Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

164 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized Phase III Study to Assess Efficacy and Safety of Adjuvant CAPOX with or without Bevacizumab in Patients after Resection of Colorectal Liver Metastases: HEPATICA study.
Snoeren N, van Hillegersberg R, Schouten SB, Bergman AM, van Werkhoven E, Dalesio O, Tollenaar RA, Verheul HM, van der Sijp J, Borel Rinkes IH, Voest EE; Hepatica study group. Snoeren N, et al. Among authors: bergman am. Neoplasia. 2017 Feb;19(2):93-99. doi: 10.1016/j.neo.2016.08.010. Epub 2017 Jan 12. Neoplasia. 2017. PMID: 28088688 Free PMC article. Clinical Trial.
A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment.
Snoeren N, Voest EE, Bergman AM, Dalesio O, Verheul HM, Tollenaar RA, van der Sijp JR, Schouten SB, Rinkes IH, van Hillegersberg R. Snoeren N, et al. Among authors: bergman am. BMC Cancer. 2010 Oct 11;10:545. doi: 10.1186/1471-2407-10-545. BMC Cancer. 2010. PMID: 20937118 Free PMC article. Clinical Trial.
CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel.
Wissing MD, Coenen JL, van den Berg P, Westgeest HM, van den Eertwegh AJ, van Oort IM, Bos MM, Bergman AM, Hamberg P, Ten Tije AJ, Los M, Lolkema MP, de Wit R, Gelderblom H. Wissing MD, et al. Among authors: bergman am. Int J Cancer. 2015 Mar 15;136(6):E760-72. doi: 10.1002/ijc.29231. Epub 2014 Oct 3. Int J Cancer. 2015. PMID: 25242736
Induction chemotherapy followed by surgery in node positive bladder cancer.
Meijer RP, Mertens LS, van Rhijn BW, Bex A, van der Poel HG, Meinhardt W, Kerst JM, Bergman AM, Fioole-Bruining A, van Werkhoven E, Horenblas S. Meijer RP, et al. Among authors: bergman am. Urology. 2014 Jan;83(1):134-9. doi: 10.1016/j.urology.2013.08.082. Epub 2013 Nov 15. Urology. 2014. PMID: 24246329
Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors.
Fizazi K, Drake CG, Beer TM, Kwon ED, Scher HI, Gerritsen WR, Bossi A, den Eertwegh AJMV, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Danielli R, Franke FA, Sundar S, Agarwal N, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengeløv L, Hansen S, McHenry MB, Chen A, Logothetis C; CA184-043, Investigators. Fizazi K, et al. Among authors: bergman am. Eur Urol. 2020 Dec;78(6):822-830. doi: 10.1016/j.eururo.2020.07.032. Epub 2020 Aug 15. Eur Urol. 2020. PMID: 32811715 Free PMC article. Clinical Trial.
The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world population.
Westgeest HM, Kuppen MCP, van den Eertwegh AJM, de Wit R, Bergman AM, van Moorselaar RJA, Coenen JLLM, van den Bergh ACM, Somford DM, Mehra N, van Oort IM, Aben KKH, Gerritsen WR, Uyl-de Groot CA. Westgeest HM, et al. Among authors: bergman am. Prostate Cancer Prostatic Dis. 2021 Sep;24(3):871-879. doi: 10.1038/s41391-021-00344-1. Epub 2021 Mar 21. Prostate Cancer Prostatic Dis. 2021. PMID: 33746212
The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer.
van Soest RJ, Nieuweboer AJ, de Morrée ES, Chitu D, Bergman AM, Goey SH, Bos MM, van der Meer N, Hamberg P, de Wit R, Mathijssen RH; Dutch Uro-Oncology Studygroup (DUOS). van Soest RJ, et al. Among authors: bergman am. Eur J Cancer. 2015 Nov;51(17):2562-9. doi: 10.1016/j.ejca.2015.07.037. Epub 2015 Aug 13. Eur J Cancer. 2015. PMID: 26278646 Clinical Trial.
Efficacy, Tolerance, and Plasma Levels of Abiraterone and Its Main Metabolites in a Patient With Metastatic Castration-resistant Prostate Cancer With a Hepatic Transplant.
van Nuland M, Janssen JM, van Hoek B, Rosing H, Beijnen JH, Bergman AM. van Nuland M, et al. Among authors: bergman am. Clin Genitourin Cancer. 2019 Oct;17(5):e893-e896. doi: 10.1016/j.clgc.2019.05.026. Epub 2019 May 30. Clin Genitourin Cancer. 2019. PMID: 31248829 No abstract available.
Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands.
Westgeest HM, Kuppen MCP, van den Eertwegh AJM, de Wit R, Coenen JLLM, van den Berg HPP, Mehra N, van Oort IM, Fossion LMCL, Hendriks MP, Bloemendal HJ, van de Luijtgaarden ACM, Ten Bokkel Huinink D, van den Bergh ACMF, van den Bosch J, Polee MB, Weijl N, Bergman AM, Uyl-de Groot CA, Gerritsen WR. Westgeest HM, et al. Among authors: bergman am. Clin Genitourin Cancer. 2019 Oct;17(5):e946-e956. doi: 10.1016/j.clgc.2019.05.018. Epub 2019 May 31. Clin Genitourin Cancer. 2019. PMID: 31439536 Clinical Trial.
164 results